SECTION B-Case study: The case study has 2 parts. You have to answer ALL questions and paste your answers in the 2 text

[answerhappygod]

Section B Case Study The Case Study Has 2 Parts You Have To Answer All Questions And Paste Your Answers In The 2 Text 1 (65.93 KiB) Viewed 44 times

SECTION B-Case study: The case study has 2 parts. You have to answer ALL questions and paste your answers in the 2 text boxes (each part max 800 words). There is also an optional upload section for drawings. A 68-year-old lady has pain in the abdomen and visits her doctor. The patient is sent to the hospital for an ultrasound scan and a range of tests. A biopsy was taken to ascertain the nature of, and diagnosis for, the condition. The patient was diagnosed with a cervix carcinoma Treatment regimens are tailored according to the cancer profile of presenting mutations and responsiveness of tumour cells to specific growth factors. Besides surgery and radiation therapy the patient was first treated with a combination of carboplatin and liposomal doxorubicin. As the cancer progressed and developed resistance against the treatment the tumour was profiled. Tumour profiling revealed that the tumour harbours acquired BRCA1/2 mutations. Consequently, the patient was switched to Olaparib. Part 1 (max 800 words) 1) What is one of the most common causes of cervix cancer? Outline the genesis of the cancer. 2) What are possible risk factors for cervix cancer and are there preventative therapeutic approaches in place? 3) Outline the rationale why the patient was switched onto Olaparib and its mechanism of action in reducing tumour growth. Part 2 (max 800 words) 1) What is the endogenous role of the target protein of Olaparib? What is the endogenous role of this protein in the context of DNA damaging agents (in non-mutated cells)? 2) Compare and discuss the mechanisms of action for the chemotherapeutics doxorubicin and carboplatin. 3) Which resistance mechanisms can the tumour have developed and how are they working? Are there specific mechanisms relevant only for carboplatin?